AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. – a US-based clinical-stage biopharmaceutical company that develops novel treatments for hypertension and chronic kidney disease.
The acquisition will grow AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107).
The drug is an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.
Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, AstraZeneca, said:
“Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.
“Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”
CinCor will take Baxdrostat into phase III trials after it showed promise in patients with treatment-resistant hypertension.
The drug was shown to significantly lower aldosterone levels without affecting cortisol levels across a wide range of doses.
Marc de Garidel, CEO CinCor, said:
“We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.
“CinCor is committed to ensuring a smooth transition of the development responsibilities to AstraZeneca once the acquisition is consummated.
“Thank you to all who have played, and will continue to play, essential roles in developing and evaluating baxdrostat as a potential novel treatment for cardiorenal diseases.”
